Chinese | English

Lingmed works with leading intelligence database providers as the exclusive partner in China to promote intelligence databases and tools for healthcare professionals, primarily focuses on business development professionals

LINGMED identifies and collaborates with European manufactures to bring a short listed medical products to meet China market's unmet needs

We take care of the product registration process in China to help our partner to enter China faster and more effectively

In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports

Biotechgate is an innovative drug /device database developed by Venture Valuation in Switzerland. Currently the database is already being well recognized in healthcare industry around the world. The database covers more than 36,000 pharma, medtech and biotech companies, over 45,000 innovative products. It also contains ~ 6,000 active licensing opportunities with detailed product information and BD contact information and more than 1,700 detailed deals information

Biotechgate has entered China market with Lingmed as its exclusive partner in 2013

EvaluatePharma is developed by Evaluate Ltd, UK; it is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Evaluate's global team of dedicated healthcare analysts employ rigorous methodologies to deliver strategic commercial analysis. The Evaluate services offer value by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity

Lingmed is the exclusive partner of Evaluate for China Market

GBI SOURCE is an online platform, currently subscribed to by over 30+ multinational pharma, biotech and consulting firms of varying sizes in China and heavily used by them day-to-day. SOURCE China tracks every product, pipeline, company, registration, hospital & physician database and market access info, includes reimbursement, tendering, retail pricing etc in the pharma& biotech industry in China, updated daily

Lingmed promotes the SOURCE platform to local domestic pharmaceutical companies and provides customer training and services for Chinese local clients

Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners

Linkedbio Partnering: Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing

Linkedbio Analysis: Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients

Venture valuation – Lingmed works with VV to bring valuation workshop into China market as well as support Chinese clients with European company Due Diligence projects
Xplico Evaluator – Business forecast tool on sales forecast and deal valuation. Xplico evaluator was developed by Danish company Xplico and launched in 2006, this excel add-on tool has been widely used by small and midsize pharmaand biotech companies In 2014, Lingmed started to introduce Xplico into China market as its exclusive partner for the first time
©Copyright 2013 - 2017 Lingmed Limited